Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449182 | 0.89 | PDE4B (0.64) | PDE4BPDE4DMAPTMEN1KMT2A | |
| SCHEMBL13159105 | 0.86 | RXFP1 (0.64) | PDE4BPDE4DMAPTMEN1KMT2A | |
| SCHEMBL3914715 | 0.85 | FLT3 (0.74) | PDE4BPDE4DMAPTMEN1KMT2A | |
| SCHEMBL8290414 | 0.81 | MEN1 (0.75) | MAPTMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL8289434 | 0.78 | RXFP1 (0.75) | PDE4BMAPTMEN1KMT2AHPGD | |
| SCHEMBL3914076 | 0.77 | MAPT (0.73) | PDE4BPDE4DMAPTMEN1KMT2A | |
| SCHEMBL8289709 | 0.76 | MAPT (0.69) | PDE4BPDE4DMAPTMEN1KMT2A | |
| SCHEMBL3914480 | 0.76 | MAPT (1.00) | PDE4BPDE4DMAPTMEN1KMT2A | |
| SCHEMBL8289822 | 0.75 | MAPT (0.68) | MAPTMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL18177310 | 0.75 | MAPT (0.61) | MAPTMEN1KMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | PDE4B 1387/4885PDE4D 1518/4885MAPT 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.